Menu
Dividend AristocratsDividend KingsHigh YieldMonthly DividendDividend CalendarScreener

Eli Lilly and Company Stock Price History

Eli Lilly and Company EPS

EPSDividend / share
-3.93.310.517.724.92008201020122014201620182020202220242025

Eli Lilly and Company Dividend per Share

Forward Yield
0.60%
Annual Dividend
6.46 USD
Payout
22.13%
Frequency
Quarterly
Yrs of growth
11
CAGR 5Y
15.18%
Status
Dividend Grower
0.01.63.24.96.519951998200120042007201020132016201920222025

Eli Lilly and Company Dividend Yield

Eli Lilly and Company Payout Ratio

0%24%48%72%96%200920112013201520182020202220242025

Eli Lilly and Company Dividend Growth

1Y CAGR
3Y CAGR
5Y CAGR
10Y CAGR
20Y CAGR
15.38%
15.24%
15.18%
11.61%
7.11%
Compound annual growth rate of dividend per share
Yield vs sector
0.60%
avg Healthcare: 2.97%
Next ex-dividend (est.)
2026-08-14
last: 2026-05-15
Ex-DateAmount
2026-05-151.73 USD
2026-02-131.73 USD
2025-11-141.50 USD
2025-08-151.50 USD
2025-05-161.50 USD
2025-02-141.50 USD
2024-11-151.30 USD
2024-08-151.30 USD

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Headquartered in Indianapolis, Indiana, the company focuses on therapies addressing diabetes, oncology, immunology, neuroscience, and cardiometabolic conditions. Its portfolio includes medicines for chronic metabolic diseases, cancer treatments aimed at specific tumor types, and immunology drugs targeting inflammatory and autoimmune disorders. Eli Lilly and Company serves healthcare systems, hospitals, and pharmacies worldwide, with a strong presence in major markets such as the United States, Europe, China, and Japan. The company operates across the full pharmaceutical value chain, from research and clinical development to large-scale manufacturing and global distribution. Through its focus on innovative, science-driven therapies for complex diseases, Eli Lilly and Company plays a significant role in the healthcare sector, supporting physicians and patients with branded medicines that are integrated into standard treatment protocols across multiple therapeutic areas.